CSIMarket



Best Performing Stocks In Medical Laboratories Industry During This Current Quarter Q3 Of 2024



 1 Day   Week  Current Month of July  30 Days 
Current Quarter Q3 of 2024  90 Days    Ytd    12 Months 
 

Shares are up by 8.98% on average, in Medical Laboratories Industry during this current quarter q3 of 2024.

Here are the best performing stocks in Medical Laboratories Industry.




PSNL

$2.98

$1.7800 148.33%
This Quarter Q3 of 2024


PSNL

$2.98

$1.7800 148.33%



Personalis Inc

Personalis Inc stock went up 148.33% during this current quarter q3 of 2024.


Personalis Inc*s business model revolves around offering advanced genomic sequencing and data analysis solutions to empower researchers and healthcare providers in their efforts to develop precision medicine and personalized therapies.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 145.109 mill. $ 70.528 mill. $ -112.780 mill. 49 mill. - Y/Y 22.81 %
Market Cap. Revenues TTM Net Income TTM

$ 145.109 mill.


$ 70.528 mill.


$ -112.780 mill.

Employees Shares Outstanding P/E

-


49 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 22.81 %


MRQ Y/Y - %



CDNA

$18.87

$10.5900 127.90%
This Quarter Q3 of 2024


CDNA

$18.87

$10.5900 127.90%



Caredx Inc

Caredx Inc stock increased 127.90% during this current quarter q3 of 2024.


Caredx Inc is a precision medicine company with a business model focused on transplant diagnostics. They develop and commercialize non-invasive tests to identify and monitor organ transplant rejection. By offering innovative solutions and services in the transplant field, Caredx Inc aims to improve outcomes for patients and provide healthcare professionals with valuable information to guide treatment decisions.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 975.435 mill. $ 275.111 mill. $ -183.194 mill. 52 mill. - Y/Y -6.75 %
Market Cap. Revenues TTM Net Income TTM

$ 975.435 mill.


$ 275.111 mill.


$ -183.194 mill.

Employees Shares Outstanding P/E

446


52 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -6.75 %


MRQ Y/Y - %



GH

$32

$15.6100 95.24%
This Quarter Q3 of 2024


GH

$32

$15.6100 95.24%



Guardant Health Inc

Guardant Health Inc stock increased 95.24% during this current quarter q3 of 2024.


Guardant Health Inc*s business model revolves around providing advanced genomic testing services for cancer patients. It specializes in developing liquid biopsy tests that analyze circulating tumor DNA (ctDNA) in the blood. These tests help in early cancer detection, treatment selection, and monitoring of cancer progression. Guardant Health Inc collaborates with healthcare providers, pharmaceutical companies, and researchers to provide these innovative tests and contribute to the advancement of precision medicine in oncology.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 3,894.784 mill. $ 603.725 mill. $ -460.901 mill. 122 mill. - Y/Y 30.90 %
Market Cap. Revenues TTM Net Income TTM

$ 3,894.784 mill.


$ 603.725 mill.


$ -460.901 mill.

Employees Shares Outstanding P/E

1,100


122 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 30.90 %


MRQ Y/Y - %



ONMD

$0.883

$0.2630 42.42%
This Quarter Q3 of 2024


ONMD

$0.883

$0.2630 42.42%



Onemednet Corporation

Onemednet Corporation stock went up 42.42% during this current quarter q3 of 2024.





Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 20.909 mill. $ 0.872 mill. $ -23.205 mill. 24 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 20.909 mill.


$ 0.872 mill.


$ -23.205 mill.

Employees Shares Outstanding P/E

-


24 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



BFLY

$1.14

$0.3206 39.13%
This Quarter Q3 of 2024


BFLY

$1.14

$0.3206 39.13%



Butterfly Network Inc

Butterfly Network Inc stock went up 39.13% during this current quarter q3 of 2024.


Butterfly Network Inc*s business model involves developing and providing handheld ultrasound devices that are portable, affordable, and user-friendly. Their products aim to revolutionize medical imaging and provide accessible healthcare solutions.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 238.116 mill. $ 67.656 mill. $ -121.921 mill. 209 mill. - Y/Y 11.63 %
Market Cap. Revenues TTM Net Income TTM

$ 238.116 mill.


$ 67.656 mill.


$ -121.921 mill.

Employees Shares Outstanding P/E

-


209 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 11.63 %


MRQ Y/Y - %



XGN

$1.92

$0.5200 37.14%
This Quarter Q3 of 2024


XGN

$1.92

$0.5200 37.14%



Exagen Inc

Exagen Inc stock improved 37.14% during this current quarter q3 of 2024.


Exagen Inc*s business model revolves around providing diagnostic testing solutions in the field of autoimmune diseases.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 34.453 mill. $ 55.733 mill. $ 4.295 mill. 18 mill. - Y/Y 28.36 %
Market Cap. Revenues TTM Net Income TTM

$ 34.453 mill.


$ 55.733 mill.


$ 4.295 mill.

Employees Shares Outstanding P/E

-


18 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 28.36 %


MRQ Y/Y - %



BDSX

$1.64

$0.4300 35.54%
This Quarter Q3 of 2024


BDSX

$1.64

$0.4300 35.54%



Biodesix Inc

Biodesix Inc shares improved 35.54% during this current quarter q3 of 2024.


Biodesix Inc is a biotechnology company that utilizes advanced diagnostics to develop personalized medicine solutions for improving patient outcomes. Their business model involves leveraging their proprietary blood-based tests and data analytics to assist healthcare providers in making informed treatment decisions. By partnering with pharmaceutical companies and healthcare institutions, Biodesix aims to commercialize their innovative solutions and drive adoption in the healthcare industry.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 130.723 mill. $ 44.026 mill. $ -63.345 mill. 80 mill. - Y/Y 21.46 %
Market Cap. Revenues TTM Net Income TTM

$ 130.723 mill.


$ 44.026 mill.


$ -63.345 mill.

Employees Shares Outstanding P/E

-


80 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 21.46 %


MRQ Y/Y - %



ISPC

$0.2833

$0.0703 33.00%
This Quarter Q3 of 2024


ISPC

$0.2833

$0.0703 33.00%



Ispecimen inc

Ispecimen Inc stock went up 33.00% during this current quarter q3 of 2024.


iSpecimen Inc*s business model revolves around connecting researchers with the biospecimens they need for their scientific and medical studies. They serve as an intermediary platform that links healthcare organizations and biobanks to the research community, providing a streamlined process for sourcing human biosamples and associated data.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 2.587 mill. $ 9.268 mill. $ -11.570 mill. 9 mill. - Y/Y -22.38 %
Market Cap. Revenues TTM Net Income TTM

$ 2.587 mill.


$ 9.268 mill.


$ -11.570 mill.

Employees Shares Outstanding P/E

-


9 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -22.38 %


MRQ Y/Y - %



PHG

$26.43

$6.2800 31.17%
This Quarter Q3 of 2024


PHG

$26.43

$6.2800 31.17%



Koninklijke Philips Nv

Koninklijke Philips Nv shares went up 31.17% during this current quarter q3 of 2024.


Koninklijke Philips Nv operates as a diversified technology company, focusing on areas such as healthcare, consumer lifestyle, and lighting. The company provides a wide range of products and solutions, including medical imaging equipment, home appliances, personal care products, and lighting solutions. Philips Nv*s business model involves innovation-driven research and development, strategic partnerships, and a global distribution network to deliver its products and services to customers worldwide.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 24,149.765 mill. $ 20,349.280 mill. $ -518.560 mill. 914 mill. - Y/Y 1.92 %
Market Cap. Revenues TTM Net Income TTM

$ 24,149.765 mill.


$ 20,349.280 mill.


$ -518.560 mill.

Employees Shares Outstanding P/E

82,000


914 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 1.92 %


MRQ Y/Y - %



RDNT

$62.62

$14.8200 31.00%
This Quarter Q3 of 2024


RDNT

$62.62

$14.8200 31.00%



Radnet Inc

Radnet Inc stock improved 31.00% during this current quarter q3 of 2024.


Radnet Inc is a medical diagnostic imaging company that operates a network of outpatient imaging centers. Their business model focuses on offering convenient and accessible imaging services to patients, partnering with healthcare providers, and leveraging technology to ensure efficient operations. By providing advanced diagnostic capabilities and collaborating with insurance companies, Radnet Inc aims to enhance patient care and streamline the imaging process.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 4,340.009 mill. $ 1,627.954 mill. $ 29.751 mill. 69 mill. - Y/Y 12.46 %
Market Cap. Revenues TTM Net Income TTM

$ 4,340.009 mill.


$ 1,627.954 mill.


$ 29.751 mill.

Employees Shares Outstanding P/E

8,700


69 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 12.46 %


MRQ Y/Y 8.92 %



VCYT

$23.47

$4.6100 24.44%
This Quarter Q3 of 2024


VCYT

$23.47

$4.6100 24.44%



Veracyte Inc

Veracyte Inc stock went up 24.44% during this current quarter q3 of 2024.


Veracyte Inc*s business model revolves around providing genomic diagnostic solutions to enable physicians to make more informed treatment decisions for patients.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 1,754.612 mill. $ 375.473 mill. $ -68.177 mill. 75 mill. - Y/Y 17.50 %
Market Cap. Revenues TTM Net Income TTM

$ 1,754.612 mill.


$ 375.473 mill.


$ -68.177 mill.

Employees Shares Outstanding P/E

677


75 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 17.50 %


MRQ Y/Y - %



INCY

$65.19

$12.4700 23.65%
This Quarter Q3 of 2024


INCY

$65.19

$12.4700 23.65%



Incyte Corporation

Incyte Corporation stock increased 23.65% during this current quarter q3 of 2024.


Incyte Corporation is a biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative medicines. Their business model revolves around extensive research and development efforts to identify potential drug candidates for various diseases. With a focus on oncology and other serious inflammatory conditions, Incyte aims to bring effective therapies to patients while collaborating with partners and leveraging their extensive intellectual property portfolio.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 14,812.407 mill. $ 3,767.865 mill. $ 745.444 mill. 227 mill. 19.81 Y/Y 8.93 %
Market Cap. Revenues TTM Net Income TTM

$ 14,812.407 mill.


$ 3,767.865 mill.


$ 745.444 mill.

Employees Shares Outstanding P/E

2,094


227 mill.


19.81

Revenue Growth Income Growth

MRQ Y/Y 8.93 %


MRQ Y/Y 681.22 %



MDXH

$2.8

$0.5000 21.74%
This Quarter Q3 of 2024


MDXH

$2.8

$0.5000 21.74%



Mdxhealth Sa

Mdxhealth Sa stock improved 21.74% during this current quarter q3 of 2024.


MDxHealth SA is a biotech company that primarily focuses on developing and commercializing molecular diagnostic tests to assist healthcare professionals in making informed treatment decisions for cancer patients. Their business model revolves around providing accurate and actionable diagnostic information to improve patient outcomes and potentially reduce healthcare costs.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 72.699 mill. $ 70.193 mill. $ -43.100 mill. 26 mill. - Y/Y 89.43 %
Market Cap. Revenues TTM Net Income TTM

$ 72.699 mill.


$ 70.193 mill.


$ -43.100 mill.

Employees Shares Outstanding P/E

-


26 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 89.43 %


MRQ Y/Y - %



NTRA

$105.51

$15.1800 16.81%
This Quarter Q3 of 2024


NTRA

$105.51

$15.1800 16.81%



Natera Inc

Natera Inc shares went up 16.81% during this current quarter q3 of 2024.


Natera Inc operates as a genetic testing company that provides non-invasive screening and diagnostic tests for reproductive health, oncology, and organ transplantation. The company*s business model is built around offering cost-effective and accurate genetic testing solutions for both patients and healthcare providers. Natera primarily generates revenue by selling its proprietary tests and associated analysis services to customers, including hospitals, laboratories, and physicians.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 12,747.085 mill. $ 1,208.556 mill. $ -365.463 mill. 121 mill. - Y/Y 52.11 %
Market Cap. Revenues TTM Net Income TTM

$ 12,747.085 mill.


$ 1,208.556 mill.


$ -365.463 mill.

Employees Shares Outstanding P/E

2,800


121 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 52.11 %


MRQ Y/Y - %



ICLR

$339.93

$47.9100 16.41%
This Quarter Q3 of 2024


ICLR

$339.93

$47.9100 16.41%



Icon Plc

Icon Plc stock increased 16.41% during this current quarter q3 of 2024.


Icon Plc is a leading provider of clinical research services, specializing in the design and management of clinical trials for pharmaceutical and biotechnology companies. Their business model focuses on offering a comprehensive range of services, including study design, data management, regulatory support, and statistical analysis, to support the development of new drugs and medical devices. Icon Plc*s success lies in its ability to provide customized solutions to its clients, efficiently navigate the regulatory landscape, and consistently deliver high-quality and timely results.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 28,118.207 mill. $ 8,120.176 mill. $ 1,236.802 mill. 83 mill. 45.94 Y/Y 4.89 %
Market Cap. Revenues TTM Net Income TTM

$ 28,118.207 mill.


$ 8,120.176 mill.


$ 1,236.802 mill.

Employees Shares Outstanding P/E

15,950


83 mill.


45.94

Revenue Growth Income Growth

MRQ Y/Y 4.89 %


MRQ Y/Y 144.76 %



DGX

$147.35

$20.3700 16.04%
This Quarter Q3 of 2024


DGX

$147.35

$20.3700 16.04%



Quest Diagnostics Inc

Quest Diagnostics Inc stock went up 16.04% during this current quarter q3 of 2024.


Quest Diagnostics Inc operates as a provider of clinical laboratory and diagnostic information services, serving patients, physicians, hospitals, and pharmaceutical companies. The company generates revenue by offering a range of diagnostic testing services, including laboratory analysis, test development, and specialized diagnostics.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 16,503.200 mill. $ 9,287.000 mill. $ 899.000 mill. 112 mill. 19.88 Y/Y 1.50 %
Market Cap. Revenues TTM Net Income TTM

$ 16,503.200 mill.


$ 9,287.000 mill.


$ 899.000 mill.

Employees Shares Outstanding P/E

49,000


112 mill.


19.88

Revenue Growth Income Growth

MRQ Y/Y 1.50 %


MRQ Y/Y -4.15 %



GNOM

$11.46

$1.5719 15.90%
This Quarter Q3 of 2024


GNOM

$11.46

$1.5719 15.90%



Complete Genomics Inc

Complete Genomics Inc shares improved 15.90% during this current quarter q3 of 2024.


Complete Genomics Inc operates in the field of genetic sequencing, offering end-to-end solutions for large-scale genomic research. They provide comprehensive DNA sequencing services, including sample preparation, sequencing, data analysis, and consulting, primarily catering to research institutions, pharmaceutical companies, and academic organizations.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 393.476 mill. $ 19.877 mill. $ -57.048 mill. 34 mill. - Y/Y -62.39 %
Market Cap. Revenues TTM Net Income TTM

$ 393.476 mill.


$ 19.877 mill.


$ -57.048 mill.

Employees Shares Outstanding P/E

-


34 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -62.39 %


MRQ Y/Y - %



MXCT

$4.51

$0.5700 14.47%
This Quarter Q3 of 2024


MXCT

$4.51

$0.5700 14.47%



Maxcyte inc

Maxcyte Inc shares went up 14.47% during this current quarter q3 of 2024.


Maxcyte Inc*s business model revolves around providing cell engineering and flow electroporation technology to facilitate drug discovery, development, and manufacturing processes.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 469.445 mill. $ 44.054 mill. $ -36.567 mill. 104 mill. - Y/Y 32.25 %
Market Cap. Revenues TTM Net Income TTM

$ 469.445 mill.


$ 44.054 mill.


$ -36.567 mill.

Employees Shares Outstanding P/E

-


104 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 32.25 %


MRQ Y/Y - %



MEDP

$437.18

$54.7400 14.31%
This Quarter Q3 of 2024


MEDP

$437.18

$54.7400 14.31%



Medpace Holdings Inc

Medpace Holdings Inc stock went up 14.31% during this current quarter q3 of 2024.


Medpace Holdings Inc is a contract research organization (CRO) that provides various services in the clinical research and development of drugs and medical devices.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 13,990.197 mill. $ 1,962.812 mill. $ 312.507 mill. 32 mill. 44.41 Y/Y 17.73 %
Market Cap. Revenues TTM Net Income TTM

$ 13,990.197 mill.


$ 1,962.812 mill.


$ 312.507 mill.

Employees Shares Outstanding P/E

3,900


32 mill.


44.41

Revenue Growth Income Growth

MRQ Y/Y 17.73 %


MRQ Y/Y 40.74 %



FLGT

$22.34

$2.2500 11.20%
This Quarter Q3 of 2024


FLGT

$22.34

$2.2500 11.20%



Fulgent Genetics Inc

Fulgent Genetics Inc shares went up 11.20% during this current quarter q3 of 2024.


Fulgent Genetics Inc is a genetic testing company that offers comprehensive, flexible, and affordable genetic testing solutions for various applications, including clinical diagnostics, carrier screening, and genetic research.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 670.490 mill. $ 285.288 mill. $ -64.981 mill. 30 mill. - Y/Y -20.64 %
Market Cap. Revenues TTM Net Income TTM

$ 670.490 mill.


$ 285.288 mill.


$ -64.981 mill.

Employees Shares Outstanding P/E

284


30 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -20.64 %


MRQ Y/Y - %



AMS

$3.25

$0.2600 8.70%
This Quarter Q3 of 2024


AMS

$3.25

$0.2600 8.70%



American Shared Hospital Services

American Shared Hospital Services shares increased 8.70% during this current quarter q3 of 2024.


American Shared Hospital Services (ASHS) operates a unique business model by providing state-of-the-art medical equipment on a shared basis to hospitals and medical centers across the United States. They establish partnerships with healthcare providers, offering the latest technology for radiation therapy, radiosurgery, and nuclear medicine without the need for significant capital investments. By leveraging their expertise and established relationships in the healthcare industry, ASHS delivers cost-effective solutions that benefit both patients and healthcare facilities alike.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 21.372 mill. $ 20.562 mill. $ 0.230 mill. 7 mill. 38.72 Y/Y 4.43 %
Market Cap. Revenues TTM Net Income TTM

$ 21.372 mill.


$ 20.562 mill.


$ 0.230 mill.

Employees Shares Outstanding P/E

-


7 mill.


38.72

Revenue Growth Income Growth

MRQ Y/Y 4.43 %


MRQ Y/Y -35.00 %



CNTG

$0.5194

$0.0394 8.21%
This Quarter Q3 of 2024


CNTG

$0.5194

$0.0394 8.21%



Centogene N v

Centogene N V shares improved 8.21% during this current quarter q3 of 2024.


Centogene N v operates in the field of rare genetic diseases, offering genetic testing and diagnostics services to patients, healthcare providers, and pharmaceutical companies. Their business model involves leveraging their extensive knowledge and expertise in genetic analysis and interpreting data to provide accurate diagnoses and personalized treatment options for individuals with rare genetic disorders. Additionally, they collaborate with pharmaceutical companies to assist in drug development and clinical trials for rare diseases.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 14.532 mill. $ 54.319 mill. $ -39.796 mill. 28 mill. - Y/Y 2.16 %
Market Cap. Revenues TTM Net Income TTM

$ 14.532 mill.


$ 54.319 mill.


$ -39.796 mill.

Employees Shares Outstanding P/E

500


28 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 2.16 %


MRQ Y/Y - %



IQV

$245.23

$17.9800 7.91%
This Quarter Q3 of 2024


IQV

$245.23

$17.9800 7.91%



Iqvia Holdings Inc

Iqvia Holdings Inc stock improved 7.91% during this current quarter q3 of 2024.


IQVIA Holdings Inc is a multinational company that operates in the healthcare industry. Its business model revolves around providing advanced analytics, technology solutions, and clinical research services to help clients make informed decisions, optimize their operations, and accelerate drug development. By leveraging its vast data resources and expertise, IQVIA aims to support healthcare professionals in improving patient outcomes and driving innovation in the industry.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 45,195.889 mill. $ 15,069.000 mill. $ 1,357.000 mill. 184 mill. 33.34 Y/Y 2.33 %
Market Cap. Revenues TTM Net Income TTM

$ 45,195.889 mill.


$ 15,069.000 mill.


$ 1,357.000 mill.

Employees Shares Outstanding P/E

79,000


184 mill.


33.34

Revenue Growth Income Growth

MRQ Y/Y 2.33 %


MRQ Y/Y -0.35 %



CELC

$18.27

$1.2600 7.41%
This Quarter Q3 of 2024


CELC

$18.27

$1.2600 7.41%



Celcuity Inc

Celcuity Inc stock increased 7.41% during this current quarter q3 of 2024.


Celcuity Inc is a biotechnology company that develops and commercializes diagnostic tests designed to classify patients* specific cancer subtypes. These tests help physicians select the most appropriate targeted therapies for their patients, ultimately improving treatment outcomes.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 614.092 mill. $ - mill. $ -74.498 mill. 34 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 614.092 mill.


$ - mill.


$ -74.498 mill.

Employees Shares Outstanding P/E

-


34 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



LH

$214.34

$14.3700 7.19%
This Quarter Q3 of 2024


LH

$214.34

$14.3700 7.19%



Laboratory Corporation Of America Holdings

Laboratory Corporation Of America Holdings stock went up 7.19% during this current quarter q3 of 2024.


Laboratory Corporation Of America Holdings operates as a leading healthcare diagnostics company. They offer a range of clinical laboratory tests and services to healthcare providers, pharmaceutical companies, and government agencies. Their business model focuses on providing accurate and timely test results, enabling healthcare professionals to diagnose, treat, and monitor patients effectively.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 18,167.108 mill. $ 11,560.300 mill. $ 434.200 mill. 85 mill. 43.30 Y/Y -15.92 %
Market Cap. Revenues TTM Net Income TTM

$ 18,167.108 mill.


$ 11,560.300 mill.


$ 434.200 mill.

Employees Shares Outstanding P/E

75,500


85 mill.


43.30

Revenue Growth Income Growth

MRQ Y/Y -15.92 %


MRQ Y/Y 7.03 %



CSTL

$19.9

$1.0600 5.63%
This Quarter Q3 of 2024


CSTL

$19.9

$1.0600 5.63%



Castle Biosciences Inc

Castle Biosciences Inc shares went up 5.63% during this current quarter q3 of 2024.


Castle Biosciences Inc is a biotechnology company that specializes in the development and commercialization of diagnostic tests for specialized cancers. Their business model revolves around leveraging molecular diagnostic technologies to provide physicians with personalized, actionable information when making treatment decisions for patients with difficult-to-diagnose or higher-risk cancers. By offering these tests, Castle Biosciences aims to improve patient outcomes and contribute to the advancement of precision medicine.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 546.952 mill. $ 250.725 mill. $ -0.132 mill. 27 mill. - Y/Y 73.59 %
Market Cap. Revenues TTM Net Income TTM

$ 546.952 mill.


$ 250.725 mill.


$ -0.132 mill.

Employees Shares Outstanding P/E

200


27 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 73.59 %


MRQ Y/Y - %



HOLX

$78.38

$3.4600 4.62%
This Quarter Q3 of 2024


HOLX

$78.38

$3.4600 4.62%



Hologic Inc

Hologic Inc shares improved 4.62% during this current quarter q3 of 2024.


Hologic Inc*s business model revolves around the development, manufacturing, and commercialization of medical technology and diagnostic products, primarily focused on women*s healthcare. They aim to provide innovative solutions for various medical specialties, including breast and skeletal health, gynecological health, and surgical products.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 18,620.110 mill. $ 4,046.300 mill. $ 621.900 mill. 238 mill. 29.92 Y/Y -0.85 %
Market Cap. Revenues TTM Net Income TTM

$ 18,620.110 mill.


$ 4,046.300 mill.


$ 621.900 mill.

Employees Shares Outstanding P/E

6,944


238 mill.


29.92

Revenue Growth Income Growth

MRQ Y/Y -0.85 %


MRQ Y/Y -22.24 %



ACON

$0.3056

$0.0087 2.93%
This Quarter Q3 of 2024


ACON

$0.3056

$0.0087 2.93%



Aclarion Inc

Aclarion Inc stock improved 2.93% during this current quarter q3 of 2024.


Aclarion Inc is a technology company that operates on a software-as-a-service (SaaS) business model. They provide their customers with cloud-based solutions, enabling them to streamline and automate their business processes efficiently. Aclarion offers a range of customizable software solutions, including data management, project management, and collaboration tools, tailored to meet the specific needs of their clients.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 1.663 mill. $ 0.060 mill. $ -6.127 mill. 5 mill. - Y/Y -60.29 %
Market Cap. Revenues TTM Net Income TTM

$ 1.663 mill.


$ 0.060 mill.


$ -6.127 mill.

Employees Shares Outstanding P/E

-


5 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -60.29 %


MRQ Y/Y - %



ENZ

$1.17

$0.0200 1.74%
This Quarter Q3 of 2024


ENZ

$1.17

$0.0200 1.74%



Enzo Biochem Inc

Enzo Biochem Inc shares went up 1.74% during this current quarter q3 of 2024.


Enzo Biochem Inc operates as a biotechnology company that specializes in the development and commercialization of innovative diagnostic and research products.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 59.690 mill. $ 32.466 mill. $ 32.566 mill. 51 mill. 0.00 Y/Y -47.65 %
Market Cap. Revenues TTM Net Income TTM

$ 59.690 mill.


$ 32.466 mill.


$ 32.566 mill.

Employees Shares Outstanding P/E

412


51 mill.


0.00

Revenue Growth Income Growth

MRQ Y/Y -47.65 %


MRQ Y/Y - %



OABI

$4.81

$0.0300 0.63%
This Quarter Q3 of 2024


OABI

$4.81

$0.0300 0.63%



Omniab Inc

Omniab Inc stock went up 0.63% during this current quarter q3 of 2024.


Omniab Inc is a technology company that operates on a B2B (business-to-business) model, offering a range of software solutions and services. The company focuses on providing customized software applications to help businesses streamline their operations, enhance productivity, and improve efficiency. Omniab Inc also offers consultation services to assist companies in optimizing their IT infrastructure.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 484.632 mill. $ 21.046 mill. $ -63.480 mill. 101 mill. - Y/Y -77.53 %
Market Cap. Revenues TTM Net Income TTM

$ 484.632 mill.


$ 21.046 mill.


$ -63.480 mill.

Employees Shares Outstanding P/E

-


101 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -77.53 %


MRQ Y/Y - %



VRDN

$14.98

$-0.1000 -0.66%
This Quarter Q3 of 2024


VRDN

$14.98

$-0.1000 -0.66%



Viridian Therapeutics Inc

Viridian Therapeutics Inc stock went down -0.66% during this current quarter q3 of 2024.


Viridian Therapeutics Inc is a biotechnology company that focuses on developing novel therapeutics to treat various diseases.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 915.264 mill. $ 0.288 mill. $ -218.125 mill. 61 mill. - Y/Y -26.53 %
Market Cap. Revenues TTM Net Income TTM

$ 915.264 mill.


$ 0.288 mill.


$ -218.125 mill.

Employees Shares Outstanding P/E

-


61 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -26.53 %


MRQ Y/Y - %



CRL

$227.62

$-2.4700 -1.07%
This Quarter Q3 of 2024


CRL

$227.62

$-2.4700 -1.07%



Charles River Laboratories International inc

Charles River Laboratories International Inc shares declined -1.07% during this current quarter q3 of 2024.


Charles River Laboratories International Inc is a contract research organization (CRO) that provides essential services and support to the pharmaceutical, biotech, and medical device industries. They offer a wide range of research models, drug discovery and development services, safety assessments, and laboratory animal medicine to assist in the preclinical and clinical stages of drug development.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 11,800.276 mill. $ 4,111.596 mill. $ 450.898 mill. 52 mill. 26.77 Y/Y -1.73 %
Market Cap. Revenues TTM Net Income TTM

$ 11,800.276 mill.


$ 4,111.596 mill.


$ 450.898 mill.

Employees Shares Outstanding P/E

20,000


52 mill.


26.77

Revenue Growth Income Growth

MRQ Y/Y -1.73 %


MRQ Y/Y -28.35 %



LUNA

$2.67

$-0.0900 -3.26%
This Quarter Q3 of 2024


LUNA

$2.67

$-0.0900 -3.26%



Luna Innovations Inc

Luna Innovations Inc shares dropped -3.26% during this current quarter q3 of 2024.


Luna Innovations Inc*s business model involves providing advanced technology solutions and services to various industries.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 94.034 mill. $ 113.692 mill. $ -1.781 mill. 35 mill. - Y/Y 17.07 %
Market Cap. Revenues TTM Net Income TTM

$ 94.034 mill.


$ 113.692 mill.


$ -1.781 mill.

Employees Shares Outstanding P/E

236


35 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 17.07 %


MRQ Y/Y - %



GEHC

$81.23

$-3.9600 -4.65%
This Quarter Q3 of 2024


GEHC

$81.23

$-3.9600 -4.65%



Ge Healthcare Technologies Inc

Ge Healthcare Technologies Inc shares declined -4.65% during this current quarter q3 of 2024.


GE Healthcare Technologies Inc*s business model is focused on providing innovative medical devices, healthcare information technology, and healthcare services to improve patient care and outcomes. The company offers a wide range of products and solutions in areas such as medical imaging, patient monitoring, diagnostics, and healthcare IT. They also collaborate with healthcare providers and partners to offer integrated solutions and support throughout the entire healthcare ecosystem.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 37,284.570 mill. $ 16,328.000 mill. $ 1,619.000 mill. 459 mill. 23.77 Y/Y -1.50 %
Market Cap. Revenues TTM Net Income TTM

$ 37,284.570 mill.


$ 16,328.000 mill.


$ 1,619.000 mill.

Employees Shares Outstanding P/E

-


459 mill.


23.77

Revenue Growth Income Growth

MRQ Y/Y -1.50 %


MRQ Y/Y 1.31 %



PMD

$2.33

$-0.2100 -8.27%
This Quarter Q3 of 2024


PMD

$2.33

$-0.2100 -8.27%



Psychemedics Corporation

Psychemedics Corporation stock dropped -8.27% during this current quarter q3 of 2024.


Psychemedics Corp*s business model is focused on providing hair drug testing services to corporate clients, law enforcement agencies, and individuals. They collect hair samples, conduct extensive laboratory analysis, and deliver accurate and confidential drug test results to their customers.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 13.528 mill. $ 20.676 mill. $ -4.458 mill. 6 mill. - Y/Y -12.58 %
Market Cap. Revenues TTM Net Income TTM

$ 13.528 mill.


$ 20.676 mill.


$ -4.458 mill.

Employees Shares Outstanding P/E

-


6 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -12.58 %


MRQ Y/Y - %



CHEK

$1.98

$-0.2000 -9.17%
This Quarter Q3 of 2024


CHEK

$1.98

$-0.2000 -9.17%



Check cap Ltd

Check Cap Ltd stock dropped -9.17% during this current quarter q3 of 2024.


Check Cap Ltd is a medical technology company that develops and commercializes an ingestible imaging capsule that allows for the detection and monitoring of colorectal polyps. Their business model revolves around manufacturing and selling this capsule device while also providing associated services and support to healthcare professionals and patients.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 11.580 mill. $ - mill. $ 17.568 mill. 6 mill. 0.66 Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 11.580 mill.


$ - mill.


$ 17.568 mill.

Employees Shares Outstanding P/E

-


6 mill.


0.66

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y -8.06 %



BNR

$7.07

$-0.9300 -11.63%
This Quarter Q3 of 2024


BNR

$7.07

$-0.9300 -11.63%



Burning Rock Biotech Limited

Burning Rock Biotech Limited shares declined -11.63% during this current quarter q3 of 2024.


Burning Rock Biotech Limited is a company that specializes in molecular diagnostics for cancer.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ - mill. $ 75.696 mill. $ -92.070 mill. - mill. - Y/Y -7.31 %
Market Cap. Revenues TTM Net Income TTM

$ - mill.


$ 75.696 mill.


$ -92.070 mill.

Employees Shares Outstanding P/E

-


- mill.


-

Revenue Growth Income Growth

MRQ Y/Y -7.31 %


MRQ Y/Y - %



BIAF

$2.53

$-0.3800 -13.06%
This Quarter Q3 of 2024


BIAF

$2.53

$-0.3800 -13.06%



Bioaffinity Technologies Inc

Bioaffinity Technologies Inc stock went down -13.06% during this current quarter q3 of 2024.


Bioaffinity Technologies Inc is a biotechnology company specializing in developing and commercializing diagnostics for various medical conditions. They utilize their patented platform technology, Affinity?, which enables the detection of cancer and other diseases at an early stage through the use of biomarkers. The company focuses on licensing their technology and partnering with diagnostic companies, aiming to provide accurate, non-invasive, and cost-effective diagnostic solutions.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 25.086 mill. $ 4.938 mill. $ -8.366 mill. 10 mill. - Y/Y 261,180.24 %
Market Cap. Revenues TTM Net Income TTM

$ 25.086 mill.


$ 4.938 mill.


$ -8.366 mill.

Employees Shares Outstanding P/E

-


10 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 261,180.24 %


MRQ Y/Y - %



LWLG

$3.53

$-0.5600 -13.69%
This Quarter Q3 of 2024


LWLG

$3.53

$-0.5600 -13.69%



Lightwave Logic Inc

Lightwave Logic Inc stock declined -13.69% during this current quarter q3 of 2024.


Lightwave Logic Inc*s business model is focused on developing and commercializing advanced photonic devices and technologies for various industries.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 419.896 mill. $ 0.030 mill. $ -21.778 mill. 119 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 419.896 mill.


$ 0.030 mill.


$ -21.778 mill.

Employees Shares Outstanding P/E

10


119 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



FOXO

$0.23

$-0.0406 -15.00%
This Quarter Q3 of 2024


FOXO

$0.23

$-0.0406 -15.00%



Foxo Technologies Inc

Foxo Technologies Inc stock went down -15.00% during this current quarter q3 of 2024.





Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 1.122 mill. $ 0.546 mill. $ -109.518 mill. 5 mill. - Y/Y -28.57 %
Market Cap. Revenues TTM Net Income TTM

$ 1.122 mill.


$ 0.546 mill.


$ -109.518 mill.

Employees Shares Outstanding P/E

-


5 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -28.57 %


MRQ Y/Y - %




 1 Day   Week  Current Month of July  30 Days 
Current Quarter Q3 of 2024  90 Days    Ytd    12 Months 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com